Logo of Chimeric Therapeutics (ASX:CHM)Latest Chimeric Therapeutics (ASX:CHM) News

Page 4
Page 4 of 4

Chimeric Therapeutics Doses First Patients in Pivotal CAR-T Trial, Raises $5M

Chimeric Therapeutics has dosed the first three patients in its Phase 1/2 CHM CDH17 CAR-T trial targeting gastrointestinal cancers, alongside advancing its AML and NK cell therapy programs. The company also secured $5 million in funding and appointed Dr Rebecca McQualter as CEO.
Ada Torres
31 Jan 2025